Clinical evaluation of microRNA expression profiling in non small cell lung cancer

被引:188
作者
Markou, A. [1 ]
Sourvinou, I. [1 ]
Vorkas, P. A. [1 ]
Yousef, G. M. [2 ]
Lianidou, E. [1 ]
机构
[1] Univ Athens, Dept Chem, Analyt Chem Lab, GR-10680 Athens, Greece
[2] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Dept Lab Med, Toronto, ON M5B 1W8, Canada
关键词
Circulating miRNAs; MicroRNAs; miR-21; Non small cell lung cancer; Tumor markers; Liquid bead array; RT-qPCR; PREDICTS SURVIVAL; NUCLEIC-ACIDS; RT-PCR; SIGNATURES; PROGNOSIS; TARGETS; TISSUES; PLASMA; BLOOD;
D O I
10.1016/j.lungcan.2013.05.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Deregulation of miRNAs expression levels has been detected in many human tumor types, and recent studies have demonstrated the critical roles of miRNAs in cancer pathogenesis. Numerous recent studies have shown that miRNAs are rapidly released from tissues into the circulation in many pathological conditions. The high relative stability of miRNAs in biofluids such as plasma and serum, and the ability of miRNA expression profiles to accurately classify discrete tissue types and disease states have positioned miRNAs as promising non-invasive new tumor biomarkers. In this study, we used liquid bead array technology (Luminex) to profile the expression of 320 mature miRNAs in a pilot testing group of 19 matched fresh frozen cancerous and non-cancerous tissues from NSCLC patients. We further validated our results by RT-qPCR for differentially expressed miRNAs in an independent group of 40 matched fresh frozen tissues, 37 plasma samples from NSCLC patients and 28 healthy donors. We found that eight miRNAs (miR-21, miR-30d, miR-451, miR-10a, miR-30e-5p and miR-126*, miR-126, miR-145) were differentially expressed by three different statistical analysis approaches. Two of them (miR-10a and miR-30e-5p) are reported here for the first time. Bead-array results were further verified in an independent group of 40 matched fresh frozen tissues by RT-qPCR. According to RT-qPCR miR-21 was significantly up-regulated (P=0.010), miR-126* (P=0.002), miR-30d (P=0.012), miR-30e-5p (P<0.001) and miR-451 (P<0.001) were down-regulated, while miR-10a was not differentiated (P=0.732) in NSCLC tissues. However, in NSCLC plasma samples, only three of these miRNAs (miR-21, miR-10a, and miR-30e-5p) displayed differential expression when compared to plasma of healthy donors. High expression of miR-21 was associated with DFI and OS both in NSCLC tissues (P=0.022 and P=0.037) and plasma (P=0.045 and P=0.065), respectively. Moreover, we report for the first time that low expression of miR-10a in NSCLC plasma samples was associated with worse DFI(P=0.050) and high expression of miR-30e-5p was found to be associated with shorter OS (P=0.048). In conclusion, circulating miR-21, miR-10a and miR-30e-5p in plasma should be further evaluated as potential non-invasive biomarkers in NSCLC. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:388 / 396
页数:9
相关论文
共 41 条
[1]   Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation [J].
Bagga, S ;
Bracht, J ;
Hunter, S ;
Massirer, K ;
Holtz, J ;
Eachus, R ;
Pasquinelli, AE .
CELL, 2005, 122 (04) :553-563
[2]   MicroRNA expression differentiates between primary lung tumors and metastases to the lung [J].
Barshack, Iris ;
Lithwick-Yanai, Gila ;
Afek, Arnon ;
Rosenblatt, Kinneret ;
Tabibian-Keissar, Hila ;
Zepeniuk, Merav ;
Cohen, Lahav ;
Dan, Harel ;
Zion, Orit ;
Strenov, Yulia ;
Polak-Charcon, Sylvie ;
Perelman, Marina .
PATHOLOGY RESEARCH AND PRACTICE, 2010, 206 (08) :578-584
[3]   Plasticity of disseminating cancer cells in patients with epithelial malignancies [J].
Bednarz-Knoll, Natalia ;
Alix-Panabieres, Catherine ;
Pantel, Klaus .
CANCER AND METASTASIS REVIEWS, 2012, 31 (3-4) :673-687
[4]   Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549) [J].
Bian, Hai-Bo ;
Pan, Xuan ;
Yang, Jin-Song ;
Wang, Zhao-Xia ;
De, Wei .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2011, 30
[5]   Accurate Classification of Non-Small Cell Lung Carcinoma Using a Novel MicroRNA-Based Approach [J].
Bishop, Justin A. ;
Benjamin, Hila ;
Cholakh, Hila ;
Chajut, Ayelet ;
Clark, Douglas P. ;
Westra, William H. .
CLINICAL CANCER RESEARCH, 2010, 16 (02) :610-619
[6]   MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer [J].
Boeri, Mattia ;
Verri, Carla ;
Conte, Davide ;
Roz, Luca ;
Modena, Piergiorgio ;
Facchinetti, Federica ;
Calabro, Elisa ;
Croce, Carlo M. ;
Pastorino, Ugo ;
Sozzi, Gabriella .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (09) :3713-3718
[7]   MicroRNA signatures in human cancers [J].
Calin, George A. ;
Croce, Carlo M. .
NATURE REVIEWS CANCER, 2006, 6 (11) :857-866
[8]   Evaluation of DNA microarray results with quantitative gene expression platforms [J].
Canales, Roger D. ;
Luo, Yuling ;
Willey, James C. ;
Austermiller, Bradley ;
Barbacioru, Catalin C. ;
Boysen, Cecilie ;
Hunkapiller, Kathryn ;
Jensen, Roderick V. ;
Knight, Charles R. ;
Lee, Kathleen Y. ;
Ma, Yunqing ;
Maqsodi, Botoul ;
Papallo, Adam ;
Peters, Elizabeth Herness ;
Poulter, Karen ;
Ruppel, Patricia L. ;
Samaha, Raymond R. ;
Shi, Leming ;
Yang, Wen ;
Zhang, Lu ;
Goodsaid, Federico M. .
NATURE BIOTECHNOLOGY, 2006, 24 (09) :1115-1122
[9]   MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs [J].
Du, Liqin ;
Schageman, Jeoffrey J. ;
Irnov ;
Girard, Luc ;
Hammond, Scott M. ;
Minna, John D. ;
Gazdar, Adi F. ;
Pertsemlidis, Alexander .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2010, 29
[10]   Use of MicroRNA Expression Levels to Predict Outcomes in Resected Stage I Non-small Cell Lung Cancer [J].
Duncavage, Eric ;
Goodgame, Boone ;
Sezhiyan, Ananth ;
Govindan, Ramaswamy ;
Pfeifer, John .
JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (11) :1755-1763